Medication info
Lozatam Plus F Tablets

Lozatam Plus F Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Light yellow oval film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200809464 · Notified 2008.09.12 · Insurance code 642903060

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this drug is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when blood pressure is controlled with this dose: Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Administration is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial losartan potassium dose of 25 mg cannot be given using this drug.
Child dose
○ Children (under 18 years of age) There is no experience with use in children and adolescents; therefore, losartan-hydrochlorothiazide combination products should not be administered to children or adolescents.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This drug is used in patients with hypertension who cannot adequately control blood pressure with monotherapy. It effectively lowers blood pressure and helps to reduce cardiovascular risks.

How to take

Adult dose

○ Adults The usual dose of this drug is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when blood pressure is controlled with this dose: Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Administration is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial losartan potassium dose of 25 mg cannot be given using this drug.

Child dose

○ Children (under 18 years of age) There is no experience with use in children and adolescents; therefore, losartan-hydrochlorothiazide combination products should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication or its components, certain kidney diseases, liver disorders, or electrolyte imbalances should not take this medication. Patients with very low blood pressure, impaired kidney function, hyperuricemia or gout, and elderly patients should use this medication with special caution. Dizziness, symptoms of low blood pressure, and electrolyte imbalance symptoms (e.g., muscle cramps, weakness) may occur, and if any unusual symptoms arise, consultation with a physician is necessary. This medication can cause dangerously high levels of potassium in the blood when taken with potassium supplements or medications containing potassium, so potassium supplements should not be taken without consulting a physician. Due to the hydrochlorothiazide component, the skin may become sensitive to sunlight, so care should be taken to use UV protection when going outdoors, and any changes in the skin should be immediately reported to a doctor. This medication may affect kidney and liver function, so regular blood tests and kidney function tests are required, and if any abnormal findings are noted, consultation with a physician is necessary. Caution is advised while driving or operating machinery as dizziness or drowsiness may occur. It is important to regularly check blood pressure and electrolyte levels as directed by a physician while taking this medication. There is no experience in using this drug in children or adolescents, so it should not be administered to them. Store out of reach of children and keep tightly closed in the original container.

Side effects

  • abdominal pain
  • swelling
  • palpitations
  • back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
Show 124 more
  • skin peeling
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • indigestion
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramp
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • nervous hyperactivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disturbances
  • drowsiness
  • tremor
  • dyspnea
  • nasal bleeding
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • eye pain
  • burning sensation
  • conjunctivitis
  • reduced vision
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsion
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasm
  • restlessness
  • renal failure
  • renal impairment
  • interstitial nephritis
  • Stevens-Johnson syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • temporary blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a light-protective container. Additionally, to prevent damage to the medication, it is important to store it at room temperature, specifically between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Light yellow oval film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.